MarkAndrewDemitrackMD

Senior Vice President and Chief Medical Officer Trevena, Inc.

Dr. Demitrack is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1988
University of California (San Francisco)Residency, Psychiatry, 1983 - 1986
Rutgers Robert Wood Johnson Medical SchoolClass of 1983

PubMed

1 citations
A Multisite, 6-Month, Open-Label Study of Maintenance Transcranial Magnetic Stimulation for Adolescents with Treatment-Resistant Depression.
Juan F Garzon, Ahmed Z Elmaadawi, Scott T Aaronson, G Randolph Schrodt Jr, Richard C Holbert
Journal of Child and Adolescent Psychopharmacology. 2024-12-26
TMS and EEG Pharmacodynamic Effects of a Selective Sphingosine-1-Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects.
Catherine M K E de Cuba, Annika A de Goede, Erica S Klaassen, Marije E Otto, Robert J Doll
Clinical Pharmacology and Therapeutics. 2024-12-06
3 citations
Neurocognitive Effect of Biased µ-Opioid Receptor Agonist Oliceridine, a Utility Function Analysis and Comparison with Morphine.
Laurence Moss, Hemme Hijma, Mark Demitrack, Jessica Kim, Geert Jan Groeneveld
Anesthesiology. 2023-12-01

Chesterbrook-Based Trevena Reduces Workforce, Continues to Evaluate Future OptionsNovember 13th, 2024
Trevena Reports First Quarter 2023 Results and Provides Business UpdateMay 15th, 2023
Trevena Reports Fourth Quarter and Full Year 2021 ResultsMarch 31st, 2022
Join now to see all